Login / Signup

Pulmonary Mycobacterium abscessus infection treated in combination with inhaled tigecycline.

Andreas Arnholdt PedersenAndreas FløeAnders LøkkeOle Hilberg
Published in: BMJ case reports (2023)
Pulmonary disease caused by Mycobacterium abscessus is difficult to treat, as there is currently no reliable evidence-based treatment. Treatment is long, complex and has many side effects. In this case, we report a patient with treatment-refractory pulmonary M abscessus disease, treated with inhaled tigecycline. Treatment with inhaled tigecycline lasted 15 months with comparably limited side effects. There were no positive mycobacterial cultures in the follow-up period of 2 years. Inhaled tigecycline is an option in the treatment of pulmonary M. abscessus when first-line treatment fails. Additional research should investigate this further.
Keyphrases
  • pulmonary hypertension
  • mycobacterium tuberculosis
  • escherichia coli
  • case report
  • pseudomonas aeruginosa
  • newly diagnosed